Objective To analyze the relations between obstructive sleep apnea and bradyarrhythmia.Methods From 1999 to 2005,203 patients who came from Bering Tongren Hospital and Fuwai Hospital were found to have sleep apnea in an ambulatory study. A Hoher electrecardiogram was recorded for 24 hours within 2 weeks after patients were diagnosed as obstructive sleep apnem Results Nocturnal episodes of bradyarrhythmia were identified in 12(5.9%)of 203 patients.Body mass index and respiratory disturbance index in patients with bradyarrhythmia(n=12)were higher than those in patientswithour bradyarrhymia(n=191)(34±5 735.24±6 and 63±15 vs.25±5,respectively,both P<0.01).There was a significant difference in end-apneic oxygen saturation in apnea/hypopnea episodes with and without bradyarrhythmia(63%±15% vs.75%±11%,P<0.05).A linear relation between end-apneic oxygen saturation and number of sinus arrests and heart blocks was not found.Conclusions Patients with apnea-associated bradyarrhythmia have higher body mflgB index and higher respiratory disturbance index than patients without bradyarrhythmi&Bradyarrhythmia occurres independently from decrease in oxygen saturation.

OBJECTIVETo investigate the expression of Toll-like receptor 4 (TLR4) in the liver tissue of rats with bile duct ligation (BDL)-induced hepatic fibrosis and evaluate the inhibitory effects of perindopril and losartan on TLR4 expression.

METHODSMale Wistar Rats were randomly divided into sham-operated group (n=6), BDL group, perindopril treatment group (2 mg/kg) and losartan treatment group (50 mg/kg) (n=12). Perindopril and losartan groups were further divided into two subgroups for corresponding treatments by gastric lavage once daily for 14 and 30 days. The protein level of TLR4 in the liver tissue was examined by Western blotting.

RESULTSIn 14-day BDL group, the protein level of TLR4 significantly increased to 6.53∓1.11 folds of that in the sham group (P<0.05), and was lowered significantly to 1.71∓0.41 folds and 0.95∓0.38 folds following perindopril and losartan treatments for 14 days. TLR4 expression significantly increased to 6.51∓0.87 folds and 5.64∓0.87 folds of that of the sham group in perindopril and losartan groups after the 30-day treatments (P<0.05).

CONCLUSIONTLR4 expression is up-regulated in the liver of rats with BDL-induced hepatic fibrosis, and can be lowered by perindopril and losartan treatmemts for 14 days.

Animals ; Bile Ducts ; surgery ; Down-Regulation ; drug effects ; Ligation ; Liver Cirrhosis, Experimental ; metabolism ; pathology ; Losartan ; pharmacology ; Male ; Perindopril ; pharmacology ; Rats ; Rats, Wistar ; Toll-Like Receptor 4 ; genetics ; metabolism

Objective:To explore the effects of intermittent oro-esophageal tube feeding (IOE) on the swallowing function, incidence of aspiration pneumonia, and nutritional status in patients with dysphagia after stroke.Methods:Randomized controlled trials (RCTs) published from the establishment of the database to October 1, 2020 were retrieved from PubMed, Embase, Web of Science, EBSCO, Elsevier, OVID, ProQuest, CNKI, VIP, and Wanfang database. Two researchers independently conducted literature search, screening, data extraction and quality evaluation based on systematic reviews using Cochrane 5.11. RevMan 5.3 was used for the Meta-analysis of the included literature.Results:A total of 21 articles were included, with a total sample size of 1 616, including 809 patients receiving IOE and 807 patients with nasal indwelling gastric tube feeding. The Meta-analysis showed that IOE could enhance the swallowing function of patients ( RR=1.31, 95% CI: 1.21-1.43, P<0.01) , reduce the incidence of aspiration pneumonia ( RR=0.43, 95% CI: 0.28-0.65, P<0.01) , increase hemoglobin content ( MD=6.73, 95% CI: 5.89-7.57, P<0.01) , serum total protein content ( MD=4.44, 95% CI: 3.69-5.20, P<0.01) , serum prealbumin content ( MD=17.45, 95% CI: 7.29-27.62, P<0.01) , and serum albumin content ( MD=1.72, 95% CI: 1.33-2.10, P<0.01) . Conclusions:IOE can improve the swallowing function, reduce the incidence of aspiration pneumonia, and improve the nutritional level of patients with dysphagia after stroke, which has positive significance in clinical practice.

Objective To investigate the efficacy and safety of camrelizumab monoclonal antibody combined with molecular-targeted therapy in elderly patients with unresectable or advanced hepatocellular carcinoma(HCC).Methods A retrospective analysis was performed for the patients with unresectable/advanced HCC who attended six hospitals from January 1,2019 to March 31,2021,and all patients received camrelizumab monoclonal antibody treatment,among whom 84.8%also received targeted therapy.According to the age of the patients,they were divided into elderly group(≥65 years)and non-elderly group(＜65 years).The two groups were assessed in terms of overall survival(OS),progression-free survival(PFS),objective response rate(ORR),disease control rate(DCR),and immune-related adverse events(irAE).The chi-square test or the Fisher's exact test was used for comparison of categorical data between groups;the independent samples t-test was used for comparison of normally distributed continuous data,and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups.The Kaplan-Meier method was used for survival analysis,and the log-rank test was used for comparison of survival curves.Univariate and multivariate Cox proportional hazards regression analyses were used to determine the independent influencing factors for PFS and DCR at 6 months.Results A total of 99 HCC patients were enrolled,with 27 in the elderly group and 72 in the non-elderly group.The elderly group had an OS rate of 67.8%,an ORR of 44.4%,and a DCR of 74.1%at 12 months and a median PFS of 6.4(95%confidence interval[CI]:3.0-12.4)months,with no significant differences compared with the non-elderly group(all P＞0.05).The median OS was unavailable for the elderly group,while the non-elderly group had an OS of 18.9(95%CI:13.0-24.8)months;there was no significant difference between the two groups(P=0.485).The univariate and multivariate Cox regression analyses showed that major vascular invasion(MVI)was an independent risk factor for PFS(hazard ratio[HR]=2.603,95%CI:1.136-5.964,P=0.024)and DCR(HR=3.963,95%CI:1.671-9.397,P=0.002)at 6 months,while age,sex,etiology of HBV infection,presence of extrahepatic metastasis,Child-Pugh class B,and alpha-fetoprotein＞400 ng/mL were not associated with PFS or DCR at 6 months.For the elderly group,the incidence rates of any irAE and grade 3/4 irAE were 51.9%and 25.9%,respectively,with no significant differences compared with the non-elderly group(P＞0.05),and skin disease was the most common irAE in both groups(39.4%).Conclusion Camrelizumab monoclonal antibody combined with molecular-targeted therapy has similar efficacy and safety in patients with unresectable/advanced HCC aged≥65 years and those aged＜65 years.MVI is associated with suboptimal response to immunotherapy and poor prognosis.

177Lu-prostate specific membrane antigen(PSMA)radio-ligand therapy has been approved abroad for advanced prostate cancer and has been in several clinical trials in China.Based on domestic clinical practice and experimental data and referred to international experience and viewpoints,the expert group forms a consensus on the clinical application of 177Lu-PSMA radio-ligand therapy in prostate cancer to guide clinical practice.